Michael Barbella, Managing Editor05.10.21
Robust growth is forecast for Europe's needle-free IV connectors market over the next six years.
Coherent Market Insights expects the sector to expand 8.7 percent annually through 2027, with the total market value growing 79.7 percent (from $246.2 billion in 2020).
Key companies in the market are focusing on product launches and approvals of novel needle-free IV connectors, which is expected to drive growth of the market during the forecast period. In 2016, Hospira, a Pfizer-owned company and provider of infusion technologies, received the CE mark approval for a new needle-free intravenous (IV) connector, Nuitiv Clear Needle-free Connector. Nuitiv was launched globally, with immediate availability in Latin America, followed by Europe in early 2016.
Moreover, key companies in the market are focusing on inorganic strategies such as mergers and acquisitions to strengthen their position in the Europe needle-free IV connectors market. In 2019, ICU Medical, Inc. acquired Pursuit Vascular, a medical devices company. Under this acquisition, the ICU Medical, Inc acquired the ClearGuard HD, a natural extension of their needle-free IV connector and other infection control technologies, which together will provide best solutions to ICU for novel needle free IV connectors development.
Among countries, United Kingdom is witnessing rising number of dialysis procedures, which is expected to increase demand for needle-free IV connectors, in order to minimize the risk of catheter contamination and catheter-related bloodstream infections (CRBSIs) and that is expected to drive the United Kingdom needle-free IV connectors market. For instance, according to Kidney Care U.K., in 2019, there were almost 30,000 people on dialysis in the United Kingdom.
The Europe needle-free IV connectors market is expected to grow steadily, owing to key companies focusing on mergers and acquisitions. For instance, in 2016, Amsino entered into a merger with ICU Medical Inc. Under this merger, ICU medical will provide its Clave technology for Amsino’s IV disposable administration and extension sets for various surgical procedures.
Key players operating in the Europe needle-free IV connectors market include Cardinal Health Inc., Amsino International Inc., ICU Medical Inc., Vygon S.A, Baxter International Inc., Becton, Dickinson and Company, B. Braun Melsungen AG, NP Medical Inc., Poly Medicure Limited, CODAN Medizinische Geräte GmbH & Co KG, and Integrity Devices Ltd.
Coherent Market Insights expects the sector to expand 8.7 percent annually through 2027, with the total market value growing 79.7 percent (from $246.2 billion in 2020).
Key companies in the market are focusing on product launches and approvals of novel needle-free IV connectors, which is expected to drive growth of the market during the forecast period. In 2016, Hospira, a Pfizer-owned company and provider of infusion technologies, received the CE mark approval for a new needle-free intravenous (IV) connector, Nuitiv Clear Needle-free Connector. Nuitiv was launched globally, with immediate availability in Latin America, followed by Europe in early 2016.
Moreover, key companies in the market are focusing on inorganic strategies such as mergers and acquisitions to strengthen their position in the Europe needle-free IV connectors market. In 2019, ICU Medical, Inc. acquired Pursuit Vascular, a medical devices company. Under this acquisition, the ICU Medical, Inc acquired the ClearGuard HD, a natural extension of their needle-free IV connector and other infection control technologies, which together will provide best solutions to ICU for novel needle free IV connectors development.
Among countries, United Kingdom is witnessing rising number of dialysis procedures, which is expected to increase demand for needle-free IV connectors, in order to minimize the risk of catheter contamination and catheter-related bloodstream infections (CRBSIs) and that is expected to drive the United Kingdom needle-free IV connectors market. For instance, according to Kidney Care U.K., in 2019, there were almost 30,000 people on dialysis in the United Kingdom.
The Europe needle-free IV connectors market is expected to grow steadily, owing to key companies focusing on mergers and acquisitions. For instance, in 2016, Amsino entered into a merger with ICU Medical Inc. Under this merger, ICU medical will provide its Clave technology for Amsino’s IV disposable administration and extension sets for various surgical procedures.
Key players operating in the Europe needle-free IV connectors market include Cardinal Health Inc., Amsino International Inc., ICU Medical Inc., Vygon S.A, Baxter International Inc., Becton, Dickinson and Company, B. Braun Melsungen AG, NP Medical Inc., Poly Medicure Limited, CODAN Medizinische Geräte GmbH & Co KG, and Integrity Devices Ltd.
